AACR 2023 | Will zolbetuximab impact the treatment landscape for gastric cancer?

Following findings from the GLOW (NCT03653507) and SPOTLIGHT (NCT03504397) trials, zolbetuximab, a novel anti-claudin 18.2 antibody, has demonstrated modest survival improvements in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the future of targeting claudin 18.2. Microsatellite instable (MSI) high and HER2 are important biomarkers, and claudin 18.2 will provide additional treatment options for patients with an unmet need. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.